Ad
AVH - Avianca Holdings S A American Depositary Shares Each...
About | Avianca Holdings S.A. American Depositary Shares (Each representing 8 preferred Shares) (NYSE:AVH)
Not available
Quote | Avianca Holdings S.A. American Depositary Shares (Each representing 8 preferred Shares) (NYSE:AVH)
| Last: | $0.88 |
|---|---|
| Change Percent: | 4.38% |
| Open: | $0.8415 |
| Close: | $0.88 |
| High: | $0.9 |
| Low: | $0.826 |
| Volume: | 535,217 |
| Last Trade Date Time: | 05/08/2020 04:47:28 am |
News | Avianca Holdings S.A. American Depositary Shares (Each representing 8 preferred Shares) (NYSE:AVH)
-
VALENCIA, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today ann...
-
VALENCIA, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today ann...
Message Board Posts | Avianca Holdings S.A. American Depositary Shares (Each representing 8 preferred Shares) (NYSE:AVH)
| Subject | By | Source | When |
|---|---|---|---|
| No posts yet. | |||
News, Short Squeeze, Breakout and More Instantly...
Avianca Holdings S.A. American Depositary Shares (Each representing 8 preferred Shares) Company Name:
AVH Stock Symbol:
NYSE Market:
Ad
-
VALENCIA, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today ann...
-
VALENCIA, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today ann...
-
Multi-Year, Multi-Million Dollar Phase 2 Award for Development of High Frequency 2-18 GHz XBAW ® Filter Technology Award Invests in Development of Akoustis’ Single-Crystal and XP3F Filter Technologies New Materials and Device Manufacturing to Target Commercial...